Tag Archives: NASDAQ:VICL

Vical Inc (VICL) was Downgraded to a Hold Rating at H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju downgraded Vical Inc (VICL – Research Report) to Hold today. The company’s shares closed on Friday at $1.05. According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with

Vical Inc Receives a Buy from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vical Inc (NASDAQ: VICL), with a price target of $3.50. The company’s shares closed yesterday at $1.22, close to its 52-week low of $1.02. According

H.C. Wainwright Thinks Vical Inc’s Stock is Going to Recover

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vical Inc (NASDAQ: VICL), with a price target of $5. The company’s shares closed on Friday at $1.57, close to its 52-week low of $1.32.

Analysts Conflicted on These Healthcare Names: Vical Inc (NASDAQ: VICL) and Proteon (NASDAQ: PRTO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vical Inc (NASDAQ: VICL) and Proteon (NASDAQ: PRTO). Vical Inc (NASDAQ: VICL) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy

A Director at Vical Inc (NASDAQ: VICL) is Buying Shares

Yesterday, a Director at Vical Inc (NASDAQ: VICL), Robert Merton, bought shares of VICL for $150K. Following this transaction Robert Merton’s holding in the company was increased by 878.88% to a total of $181.4K. Based on Vical Inc’s latest earnings

Vical Inc Gets a Buy Rating from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vical Inc (NASDAQ: VICL), with a price target of $9. The company’s shares closed yesterday at $2.46. According to TipRanks.com, Selvaraju is ranked 0 out